The study published on May 28,
2024, in the Journal of Dietary
Supplements revealed significant D-mannose
limitations compared to Ellura on anti-adhesion activity against
UTI-causing bacteria.
ATLANTA, July 22,
2024 /PRNewswire/ -- Solv Wellness®, a
women's health company with a focus on pelvic health, is announcing
groundbreaking research showing that Ellura®, a 36mg
proanthocyanidin (PAC) standardized cranberry juice-based dietary
supplement, provides consumers with more broad-spectrum benefit
against UTI-causing bacteria than D-mannose.
Urinary tract infections (UTI) are caused by bacteria adhering
to the walls of the urinary tract, so preventing this step allows
the bacteria to flush harmlessly out of the body in the urine
stream. In the Journal of Dietary Supplements study,
participants took either Ellura or D-mannose over 1-week periods
and collected their urines at various time points. Urines were then
tested for bacterial anti-adhesion activity (AAA) against P-type
and Type 1 Escherichia coli (E. coli), the two most
common UTI-causing bacteria.
Results demonstrated that Ellura effectively and consistently
prevented adhesion of both types of E. coli, but D-mannose's
AAA was inconsistent and notably limited, particularly against
P-type E. coli which are implicated in causing potentially
serious kidney infections.
While both cranberry supplements and D-mannose are commonly used
to help prevent UTIs, it is critical that healthcare providers and
UTI sufferers are aware of which ingredients are scientifically
validated and proven to support optimal urinary tract health.
Key Findings from the Study
- D-mannose did not prevent the adhesion of P-type E. coli
in urine, a bacteria that can cause kidney infections.
- After taking D-mannose, there was some AAA against Type 1
E. coli in urine that can lead to bladder infections, but it
was not consistent. This activity could not be directly attributed
to D-mannose, but to an adhesion inhibitor the body naturally
produces called Tamm-Horsfall protein. These results cast doubt on
the benefits of taking D-mannose for the maintenance of urinary
tract health.
- Ellura significantly prevented adhesion of both P-type and Type
1 bacteria in a consistent manner over the course of the
study.
- The effectiveness of Ellura was mainly attributed to its
active ingredient, 36mg of soluble (bioavailable) juice-based PAC,
the cranberry component that has demonstrated potent bacterial AAA
in many previous studies.
This Journal of Dietary Supplements study comes on the
heels of a large-scale clinical trial of nearly 600 women
published in April 2024 in the
Journal of the American Medical Association (JAMA) Internal
Medicine that found no reduction in recurrent UTIs when
D-mannose was taken daily over 6 months. The authors concluded that
D-mannose should not be recommended for UTI prevention.
Results of the new study support the JAMA clinical
findings, providing further insights into the lack of effectiveness
of D-mannose and positioning Ellura as the clear alternative,
providing broad-spectrum, reliable benefits for maintaining urinary
tract health. Read the full press release of the JAMA study
here.
Moreover, the results address the concerns highlighted in
the 2022 Cochrane Database of Systematic
Reviews where it is stated, "There is currently little to
no evidence to support or refute the use of D-mannose to prevent or
treat UTIs in all populations." By demonstrating the limited
efficacy of D-mannose and establishing Ellura, with its
standardized 36mg level of highly active cranberry PAC, as a more
effective choice for preventing adhesion of the bacteria that cause
UTIs, healthcare providers and recurrent UTI sufferers have more
valuable insights into evidence-based UTI management
strategies.
Understanding Effective Cranberry Supplements
Current study researchers make a significant point that should
be heavily considered by consumers when assessing the bioactivity
of different cranberry supplements. They explain not every
cranberry supplement provides sufficient AAA, which is why it's
critical for consumers to take a urinary tract health supplement
that contains 100% soluble PAC extracted from only pure cranberry
juice, like Ellura.
Amy Howell, PhD, Philip E.
Marucci Center for Blueberry & Cranberry Research, Rutgers University and lead researcher, has been a
key force in determining the impact of cranberry PAC on bacteria
adhesion in the urinary tract and its necessary dosing for
proven effectiveness over the last 30 years. In a
NutraIngredients article on the study, she further
explains that not all cranberry supplements are created equal:
"Many lower cost supplements contain
the pomace fiber material left over after the juice is removed and
are not as effective at preventing bacterial adhesion as compared
to a pure juice-based product."
Her statement is supported by a 2022 study where Ellura and
another cranberry supplement made up of mostly pomace (the skin,
seeds, and pulp of the berry) were tested. It was concluded the
juice-based PAC in Ellura was highly effective at preventing P-type
AAA as compared to the pomace-derived product.
Concluding Thoughts
Terri Wade, CEO of Solv Wellness,
shares, "Ellura's consistent performance against UTI-causing
bacteria proves its unmatched efficacy. At Solv Wellness, our
commitment to delivering science-backed solutions remains
unwavering, and we are proud to showcase another successful study
highlighting Ellura as the premier UTI supplement to help defend
against UTIs."
Ellura by Solv Wellness stands out as the only cranberry
supplement on the market today that delivers all the components
needed for an effective UTI supplement: 36mg of 100% cranberry
juice–based PAC for maximum solubility (bioavailability) and AAA,
resulting in the highest effectiveness.
Ellura by Solv Wellness is backed by 21 clinical studies, and 19
traditional medicine approvals worldwide.
About Solv Wellness, LLC
Solv Wellness, LLC, delivers products backed by science for
often stigmatized pelvic health conditions. For too long, women's
needs at midlife and beyond have been underserved by the scientific
and healthcare communities, and as a result, many women often dread
much of what aging brings. Solv Wellness is committed to helping
women stay optimistic about the future by providing meaningful
solutions, backed by science, to the issues women experience at
midlife and beyond. Solv Wellness is the company behind
Ellura®, Via™, and Māge™. Ellura is a clinically proven
UTI supplement for non-antibiotic management of recurrent urinary
tract infections. Via is a vaginal moisturizer made with the
highest-quality ingredients that help replenish moisture where
women need it most. Māge is a state-of-the-art pre- and probiotic
supplement that helps support the entire female pelvic triangle:
the gut, vagina, and urinary tract.
For more information about Solv Wellness and its product
offerings, visit solvwellness.com.
For scientific data, dosing information, and more, please
visit hcp.solvwellness.com.
Contact Info:
Candice Mailman
Senior Marketing Manager
candice@solvwellness.com
609-731-9646
Statements in this release have not been evaluated by the
FDA.
These products are not intended to diagnose, treat, cure, or
prevent any disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-study-shows-ellura-uti-supplement-provides-more-consistent-and-broader-benefit-than-d-mannose-against-uti-bacteria-302202753.html
SOURCE Solv Wellness®